MetaCap

BlossomHill Therapeutics (BLSM) vs CytomX Therapeutics (CTMX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.

Summary

CytomX Therapeutics is the larger company by market cap ($555.6 million vs $527.9 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BLSM+3.81%CTMX-26.30%
+72%+21%-31%
Aug 7, 20261 yearOct 7, 2026
BLSM+3.81%CTMX-26.30%
+65%+17%-31%
Aug 3, 20265 yearsOct 5, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BLSM versus CTMX key metrics
MetricBLSMCTMX
Share price$16.61$2.55
Market cap$527.95M$555.64M
1-day change-3.93%-0.39%
YTD return—-40.14%
1-year return—-23.42%
5-year return—-50.39%
EPS (TTM)$-4.70$-0.51
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
52-week high$27.99$8.21
52-week low$15.25$2.48
Distance from 52-week high-40.66%-68.94%
Average volume263.69K3.36M
Shares outstanding31.78M217.90M
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

BLSM vs CTMX FAQ

Which is bigger, BlossomHill Therapeutics or CytomX Therapeutics?

CytomX Therapeutics (CTMX) is larger, with a market capitalization of $555.64M compared with $527.95M for BlossomHill Therapeutics (BLSM).

Are BlossomHill Therapeutics and CytomX Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons